The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Novel therapeutic approaches for pulmonary fibrosis
Open accessAbstract
Pulmonary fibrosis represents the end stage of a number of heterogeneous conditions and is, to a greater or lesser degree, the hallmark of the interstitial lung diseases. It is characterized by the excessive deposition of extracellular matrix proteins within the pulmonary interstitium leading to the obliteration of functional alveolar units and in many cases, respiratory failure. While a small number of interstitial lung diseases have known aetiologies, most are idiopathic in nature, and of these, idiopathic pulmonary fibrosis is the most common and carries with it an appalling prognosis – median survival from the time of diagnosis is less than 3 years. This reflects the lack of any effective therapy to modify the course of the disease, which in turn is indicative of our incomplete understanding of the pathogenesis of this condition. Current prevailing hypotheses focus on dysregulated epithelial–mesenchymal interactions promoting a cycle of continued epithelial cell injury and fibroblast activation leading to progressive fibrosis. However, it is likely that multiple abnormalities in a myriad of biological pathways affecting inflammation and wound repair – including matrix regulation, epithelial reconstitution, the coagulation cascade, neovascularization and antioxidant pathways – modulate this defective crosstalk and promote fibrogenesis. This review aims to offer a pathogenetic rationale behind current therapies, briefly outlining previous and ongoing clinical trials, but will focus on recent and exciting advancements in our understanding of the pathogenesis of idiopathic pulmonary fibrosis, which may ultimately lead to the development of novel and effective therapeutic interventions for this devastating condition. LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue‐1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedThalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 2×
“The Th hypothesis of fibrosis proposes that progressive pulmonary fibrosis results from a maladaptive immune response, dominated by Th2 cytokines, such as interleukin (IL)-13, to a persistent inciting agent [reviewed in (Wynn, 2004)].”
BackgroundMyofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Wipff, P.-J., Rifkin, D. B., Meister, J.-J., & Hinz, B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704042 · Cited by 1,346
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell
Kagan, H. M., & Li, W. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10413 · Cited by 954
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J., Kaminski, N., & Abraham, E. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100035 · Cited by 935 · cited 2×
“In contrast, a second study focused on miR-21 – this is up-regulated in human IPF lung specimens, as well as in the murine bleomycin model (Liu et al., 2010a).”
BackgroundBarry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury
Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T. R., Horowitz, J. C., Pennathur, S., Martinez, F. J., & Thannickal, V. J. (2009) · Nature Medicine · doi:10.1038/nm.2005 · Cited by 852 · cited 2×
“However, recent work has demonstrated that similar benefits may be observed when redressing this redox imbalance from the opposite side of the equation: NADPH oxidase (NOX)-4 catalyses the reduction of O2 to ROS, and genetic and pharmacological targeting of NOX-4 attenuates experimentally induced fibrosis, possibly by…”
BackgroundTager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823 · cited 2×
“The potential significance of this mediator in lung fibrosis has been highlighted by studies demonstrating a critical role for LPA1 activation in fibroblast recruitment and vascular leak following experimentally induced lung injury in mice (Tager et al., 2008).”
BackgroundBUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718 · cited 4×
“The BUILD-1 trial (Actelion, Switzerland) evaluated the effect of bosentan administration in patients with IPF but no evidence of severe pulmonary hypertension (PHT) (King et al., 2008).”
BackgroundInfluentialGressner, A. M., & Weiskirchen, R. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00292.x · Cited by 718 · cited 1×
“In the liver, pericytes, or hepatic stellate cells, are the principal collagen-producing cell in hepatic fibrosis [reviewed in (Gressner and Weiskirchen, 2006)].”
BackgroundAberrant Wnt/β-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis
Chilosi, M., Poletti, V., Zamò, A., Lestani, M., Montagna, L., Piccoli, P., Pedron, S., Bertaso, M., Scarpa, A., Murer, B., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64282-4 · Cited by 708
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652 · cited 1×
“Post hoc analysis of a second, similarly designed trial (Raghu et al., 2004), suggested that patients with relatively well-preserved lung function may have a survival benefit with IFN-g treatment.”
MethodA Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.-H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411703 · Cited by 586
Königshoff, M., Kramer, M., Balsara, N., Wilhelm, J., Amarie, O. V., Jahn, A., Rose, F., Fink, L., Seeger, W., Schaefer, L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci33950 · Cited by 558
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420 · cited 2×
“Expression of this integrin is low in normal epithelial tissues and is significantly up-regulated in injured and inflamed epithelia (Breuss et al., 1995) including the activated epithelium in IPF (Horan et al., 2008).”
BackgroundUric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Pétrilli, V., Tschopp, J., Lagente, V., Quesniaux, V. F. J., Ryffel, B., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1274oc · Cited by 410 · cited 4×
“, 2009); a major role for uric acid as the danger signal to the NALP-3 inflammasome following experimental lung injury has been described and the prophylactic administration of allopurinol or uricase, strategies aimed at reducing uric acid levels, attenuated bleomycin-induced fibrosis in this model (Gasse et al., 2009…”
BackgroundInfluentialImatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373 · cited 1×
“In a recent multi-centre, randomized, placebo-controlled trial (Novartis, Switzerland) of patients with mild to moderate IPF followed for 96 weeks (Daniels et al., 2010) imatinib did not affect survival or lung function.”
BackgroundTreatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370 · cited 2×
“…to these promising preclinical studies, the soluble TNF-a receptor antagonist Etanercept proved disappointing in a subsequent randomized, double-blinded, placebo-controlled trial (Wyeth, USA) in IPF patients with no significant improvement in lung function parameters observed (Raghu et al., 2008).”
BackgroundResultKuwano, K., Kunitake, R., Kawasaki, M., Nomoto, Y., Hagimoto, N., Nakanishi, Y., & Hara, N. (1996) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.154.2.8756825 · Cited by 339
Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., & Moore, B. B. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2002-0243oc · Cited by 294 · cited 4×
“PGE2 exerts major anti-fibrotic effects by suppressing fibroblast responses, including proliferation (Bitterman et al., 1986; Lama et al., 2002), differentiation into myofibroblasts (Kolodsick et al., 2003) and collagen synthesis (Goldstein and Polgar, 1982).”
BackgroundInfluentialPlataki, M., Koutsopoulos, A. V., Darivianaki, K., Delides, G., Siafakas, N. M., & Bouros, D. (2005) · Chest · doi:10.1378/chest.127.1.266 · Cited by 237
Bitterman, P. B., Wewers, M. D., Rennard, S. I., Adelberg, S., & Crystal, R. G. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112364 · Cited by 232 · cited 2×
“PGE2 exerts major anti-fibrotic effects by suppressing fibroblast responses, including proliferation (Bitterman et al., 1986; Lama et al., 2002), differentiation into myofibroblasts (Kolodsick et al.”
BackgroundInterleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts
Oriente, A., Fedarko, N. S., Pacocha, S. E., Huang, S.-K., Lichtenstein, L. M., & Essayan, D. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35380-7 · Cited by 230
Mizuno, S., Matsumoto, K., Li, M.-Y., & Nakamura, T. (2005) · The FASEB Journal · doi:10.1096/fj.04-1535fje · Cited by 177 · cited 2×
“, 2000), and HGF further exerts a pro-apoptotic effect on myofibroblasts via the c-Met receptor (Mizuno et al., 2005).”
BackgroundPotential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro
Saito, A., Okazaki, H., Sugawara, I., Yamamoto, K., & Takizawa, H. (2003) · International Archives of Allergy and Immunology · doi:10.1159/000073718 · Cited by 167
Moodley, Y. P., Scaffidi, A. K., Misso, N. L., Keerthisingam, C., McAnulty, R. J., Laurent, G. J., Mutsaers, S. E., Thompson, P. J., & Knight, D. A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63658-9 · Cited by 165 · cited 2×
“Myofibroblasts isolated from the lungs of IPF patients also exhibit an enhanced migratory phenotype (Suganuma et al., 1995) and are capable of releasing numerous pro-fibrotic mediators (Moodley et al., 2003).”
BackgroundEffect of pirfenidone on rat hepatic stellate cell proliferation and collagen production
Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Casini, A., Ceni, E., Saccomanno, S., Marzioni, M., Trozzi, L., Sterpetti, P., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00245-3 · Cited by 138 · cited 2×
“Briefly, pirfenidone has been shown to inhibit fibroblast proliferation and collagen synthesis in vitro (Hewitson et al., 2001; Di Sario et al., 2002) as well as inhibiting TGF-b induced heat shock protein HSP47 expression, a molecular chaperone of collagen, the synthesis of which is known to…”
BackgroundGlutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis
Beeh, K. M., Beier, J., Haas, I. C., Kornmann, O., Micke, P., & Buhl, R. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00262402 · Cited by 132
Regulation of fibroblast functions by lysophospholipid mediators: Potential roles in wound healing
Watterson, K. R., Lanning, D. A., Diegelmann, R. F., & Spiegel, S. (2007) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00292.x · Cited by 113
Rosenbloom, J., Feldman, G., Freundlich, B., & Jimenez, S. A. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290706 · Cited by 101
Cited by
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Pulmonary fibrosis: patterns and perpetrators
Noble, P. W., Barkauskas, C. E., & Jiang, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60323 · Cited by 595
Diverse functions of matrix metalloproteinases during fibrosis
Giannandrea, M., & Parks, W. C. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.012062 · Cited by 541
Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions
Della Latta, V., Cecchettini, A., Del Ry, S., & Morales, M. A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.012 · Cited by 514
Mesenchymal stem cells in fibrotic disease
El Agha, E., Kramann, R., Schneider, R. K., Li, X., Seeger, W., Humphreys, B. D., & Bellusci, S. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.011 · Cited by 430
Metadata
- Authors
- Datta, A., Scotton, C. J., & Chambers, R. C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-04-06
- Volume
- 163
- Issue
- 1
- Pages
- 141-172
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1687290736
- Cited by
- 202
- References
- 35
- FWCI
- 13.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.